Discovery of a novel HCV helicase inhibitor by a de novo drug design approach.

Herein we report a successful application of a computer-aided design approach to identify a novel HCV helicase inhibitor. A de novo drug design methodology was used to generate an initial set of structures that could potentially bind to a putative binding site. Further structure refinement was carried out through docking a series of focused virtual libraries. The most promising compound was synthesised and it exhibited a submicromolar inhibition of the HCV helicase.

[1]  Michael Hedrick,et al.  Total Synthesis of Distamycin A and 2640 Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity , 2000 .

[2]  J P Griffith,et al.  Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. , 1998, Structure.

[3]  E. Novellino,et al.  Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. , 2005, Biochemistry.

[4]  M. Alaoui-Ismaili,et al.  A novel high throughput screening assay for HCV NS3 helicase activity. , 2000, Antiviral research.

[5]  David N. Frick,et al.  Two Novel Conserved Motifs in the Hepatitis C Virus NS3 Protein Critical for Helicase Action* , 2003, Journal of Biological Chemistry.

[6]  A. Fattom,et al.  Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. , 2003, Journal of medicinal chemistry.

[7]  N. Hayashi,et al.  Antiviral therapy for chronic hepatitis C: past, present, and future , 2005, Journal of Gastroenterology.

[8]  V. Soriano,et al.  New therapies for hepatitis C virus infection. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  E. Chinje,et al.  Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase. , 2003, Bioorganic & medicinal chemistry.

[10]  P. Herdewijn,et al.  Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[11]  H. Blum,et al.  Molecular Virology of Hepatitis C Virus (HCV): 2006 Update , 2006, International journal of medical sciences.

[12]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[13]  David N. Frick,et al.  Hepatitis C Virus Subgenomic Replicon Requires an Active NS3 RNA Helicase , 2006, Journal of Virology.

[14]  Jane Collier,et al.  Development of novel treatments for hepatitis C. , 2009, The Lancet. Infectious diseases.

[15]  Luhua Lai,et al.  LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design , 2000 .